Breast cancer peptide coverage on Peptide News Digest is dominated by peptide cancer vaccines and peptide-drug conjugates. The most cited 2026 read: BriaCell's Bria-IMT plus checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in a registration-enabling Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy.
Other programs: Greenwich LifeSciences' GP2 / GLSI-100 HER2 peptide vaccine, Roche's breast-cancer pill (part of the Q1 2026 strategy reset), and academic peptide-vaccine work in triple-negative breast cancer.
Stories here cover trial readouts, AACR and ASCO presentations, and the broader immunotherapy pipeline. See #metastatic-breast-cancer, #triple-negative-breast-cancer, and #peptide-vaccine.
Tongji University researchers used 365 nm UV light and a photoinitiator to polymerize a histidine-based monomer inside inflammatory breast cancer cells, forming peptide nanosheets about 30 nm thick that stiffened the cells, reduced their migration and invasion, and triggered a paraptosis-like cell death, they reported in ACS Nano. In mice with implanted tumors, light delivered through an optical fiber inhibited tumor growth by 72.2% without overt systemic toxicity; there is no human data.
Researchers at Jefferson Einstein Philadelphia Hospital reported in Supportive Care in Cancer on October 27, 2026 a TriNetX study of 61,630 propensity-matched adults with breast cancer who had a mastectomy or underarm lymph node procedure. Coded postmastectomy lymphedema, arm swelling caused by damaged lymph drainage, was recorded in 0.88% of GLP-1 users versus 2.58% of nonusers over up to 650 days (hazard ratio 0.37), an absolute difference of 1.7 percentage points. The study relied on diagnosis codes and cannot show that the drugs prevented lymphedema.
Mount Sinai Hospital breast oncologists reported in Breast Cancer Research and Treatment on October 26, 2026 a retrospective study of 269 patients taking a GLP-1 drug for at least a year alongside adjuvant endocrine therapy for hormone receptor-positive breast cancer. Average weight loss at 12 months was 4.5% (3.9 kg), with 21.3% losing at least 10% and 10.4% at least 15%; semaglutide users lost 5.8% and tirzepatide users 4.7%, while dulaglutide users were unchanged. Patients whose tumors were PR-negative lost more than PR-positive patients (8.2% vs 4.2%), 70.6% had type 2 diabetes, and the single-center design means the comparison with trial results is indirect.
Researchers at Brazil's State University of Campinas (UNICAMP) reported in Immunology on October 25, 2026 that LW-9, a peptide isolated from the venom of the Brazilian wandering spider Phoneutria nigriventer, delayed tumor growth in mice with EO771 breast tumors, with a stronger effect combined with the chemotherapy drug doxorubicin. At 1 µg/kg it caused no significant changes in liver or kidney markers, and mice given it with doxorubicin ate more and held their weight better than mice on doxorubicin alone. Tumors in the combination group had less PD-L1 and more T cells, including GITR-positive T cells; the work is in mice.
Plastic surgeons at Ajou University School of Medicine in South Korea reported in Aesthetic Plastic Surgery on October 24, 2026 a randomized, active-controlled trial in patients receiving radiation after mastectomy and breast reconstruction, comparing a cream containing NeoPep-S, a peptide derived from the protein AIMP1, with a standard barrier-repair moisturizer. Of 30 patients randomized 2:1, 23 completed the study (15 vs 8): skin water loss recovered similarly at one month, scar scores were significantly better with NeoPep-S at three months, pain was lower at both visits, and itching resolved completely in 100% versus 50%. The trial was small, and about a quarter of participants did not finish.
Researchers at the Macau University of Science and Technology, with a co-author from drugmaker Livzon, reported in Advanced Science on October 18, 2026 a lipid depot loaded with VDAP, an anticancer peptide derived from an HIV protein, that changes its internal structure and releases the peptide faster in the acidic tissue left after tumor removal. In mice with incompletely removed breast tumors, the depot killed remaining tumor cells in a way that alerted the immune system, increased tumor-fighting T cells, and reduced regrowth and lung metastases. The work is in mice.
Researchers at the First Affiliated Hospital of Soochow University in China reported in the Journal of Nuclear Medicine on October 8, 2026 a gallium-68 tracer built on a dimeric (two-unit) cyclic peptide, [68Ga]Ga-TDN1, that binds nectin-4, a tumor protein also targeted by the antibody-drug conjugate enfortumab vedotin (Padcev). After animal tests showed specific tumor uptake, a first-in-human pilot in six breast cancer patients found it performed comparably to standard FDG PET for primary tumors and lymph nodes and detected bone and liver metastases better. The tracer was well tolerated; the human study is very small.
AstraZeneca (NASDAQ: AZN) announced Friday September 4, 2026 that the FDA granted accelerated approval to Etcamah (camizestrant, an oral selective estrogen receptor degrader) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone-receptor-positive HER2-negative locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy. FDA also approved the Guardant360 CDx blood-based next-generation sequencing assay as a companion diagnostic to identify ESR1-mutant patients. Approval was based on the Phase 3 SERENA-6 trial that documented a 56% reduction in disease progression or death versus continued standard-of-care aromatase inhibitor plus CDK4/6 inhibitor treatment in the ESR1-mutated subgroup. SERENA-6 was presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine. Etcamah becomes the first oral SERD approved for the switch-at-emergence-of-ESR1 setting, replacing the fulvestrant intramuscular injection historically used post-progression. AstraZeneca is positioning Etcamah alongside Trodelvy plus Datroway as anchors of the expanded breast-cancer franchise.
A separate ASCO 2026 analysis examined outcomes in patients with breast cancer and co-existing obesity or type 2 diabetes who received GLP-1 receptor agonists — adding breast-cancer-specific depth to the broader GLP-1-and-cancer signal that ran through the meeting. The analysis sits alongside Abstract 3143 (the 12,112-patient study showing 38-50% lower metastatic progression across four obesity-related cancers, with breast cancer at 10% vs 20% metastasis on GLP-1 vs gliptin) and the Roswell Park aggressive-breast-cancer analysis. The consistent theme across the ASCO 2026 GLP-1 oncology slate: in obesity-related and metabolically-driven cancers, GLP-1 therapy appears associated with better outcomes, with the strongest and most mechanistically interpretable signal in breast cancer where high tumor GLP-1 receptor expression tracked with 45% lower mortality. Adverse-event rates matched the comparator groups with no increase in pancreatitis or other GLP-1-associated concerns in the cancer setting. The data is observational and not yet RCT-grade, but the breast-cancer consistency across multiple independent analyses strengthens the case for prospective study.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
Greenwich LifeSciences presented FLAMINGO-01 Phase III open-label data at AACR 2026 showing GLSI-100 (the 9-amino-acid GP2 HER2 peptide plus GM-CSF adjuvant) produced a ~4x increase in delayed-type hypersensitivity to GP2 across 247 non-HLA-A*02 patients — from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). GP2 is the C-terminal transmembrane fragment of the HER2/neu protein.
BriaCell's Bria-IMT + checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in its pivotal Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy. Phase 2 biomarker analyses identified mitotic circulating tumor cells as prognostic and PD-L1 in tumor-macrophage fusion cells as predictive of checkpoint benefit. Presented at AACR April 20.